Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

One of the oldest patients with Neuromyelitis Optica in the literature.
The risk of fracture in incident multiple sclerosis patients: The Danish National Health Registers.
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.
[The role of chronic venous insufficiency in the pathogenesis of brain diseases].
Fat-soluble vitamins as disease modulators in multiple sclerosis.
New management algorithms in multiple sclerosis.
OnabotulinumtoxinA (Botox(®)): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury.
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Riluzole.
Glycans of myelin proteins.
NMO spectrum presenting as partial myelitis.
Erythrocyte membrane Fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils.
The long-term cost-effectiveness of the use of Functional Electrical Stimulation for the correction of dropped foot due to upper motor neuron lesion.
A comparison of 12 weeks of pilates and aquatic training on the dynamic balance of women with mulitple sclerosis.
The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
Molecular cloning of a human cannabinoid receptor which is also expressed in testis.
The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires Activation of the Sphingosine 1-Phosphate Receptor Subtype 1.
Oral laquinimod for multiple sclerosis.
Animal models of multiple sclerosis: the good, the bad and the bottom line.
Acute transverse myelitis: an unusual complication of typhoid fever.
Finax: Cheap Buy Cod
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.

Pages